A phase 2 clinical trial of everolimus plus bicalutamide for castration‐resistant prostate cancer
BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
H Chow, PM Ghosh, R deVere White, CP Evans… - Cancer, 2016 - europepmc.org
Background The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
[HTML][HTML] A Phase II clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
H Chow, PM Ghosh, RV White, CP Evans, MA Dall'Era… - Cancer, 2016 - ncbi.nlm.nih.gov
Background The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
A phase 2 clinical trial of everolimus plus bicalutamide for castration‐resistant prostate cancer
H Chow, PM Ghosh, RV White, CP Evans, MA Dall'Era… - Cancer, 2016 - infona.pl
BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
H Chow, CX Pan, M DallEra, S Yap, Y Li, L Beckett… - Cancer, 2016 - escholarship.org
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
H Chow, PM Ghosh, RV White, CP Evans… - Cancer, 2016 - pubmed.ncbi.nlm.nih.gov
Background The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
H Chow, PM Ghosh, R Devere White, CP Evans… - Cancer, 2016 - hero.epa.gov
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
H Chow, PM Ghosh, R deVere White, CP Evans… - Cancer, 2016 - escholarship.org
BackgroundThe mammalian target of rapamycin (mTOR) pathway is up-regulated in
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …
castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …